Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Core Insights - Chimerix granted inducement awards of non-statutory stock options to six new employees, totaling 355,000 shares of common stock [1] - The stock options have an exercise price equal to the closing trading price on the grant date, a 10-year term, and will vest over four years [2] - Chimerix is focused on developing medicines for patients with deadly diseases, with its lead program targeting H3 K27M-mutant glioma [3] Group 1 - The Compensation Committee of Chimerix's Board of Directors approved the stock options as an inducement for new employees [1] - The vesting schedule includes one-fourth vesting on the one-year anniversary of hire, with the remaining three-fourths vesting in equal monthly installments over the next three years [2] - The stock options were granted outside of the 2024 Equity Incentive Plan but are subject to its terms [2] Group 2 - Chimerix's most advanced clinical-stage program is dordaviprone (ONC201), aimed at treating H3 K27M-mutant glioma [3] - The company is also conducting Phase 1 dose escalation studies of ONC206 to evaluate safety and pharmacokinetics [3]